Clinical Report: Musings from The Power List: Ali Tavassoli

Overview

Ali Tavassoli highlights significant advancements in cyclic peptide drug discovery and the evolving landscape of druggable targets.

Background

The cyclic peptide space has seen considerable growth, with increasing recognition of previously deemed undruggable targets. This shift is crucial as it opens new avenues for drug discovery.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

• Tavassoli received the Royal Society of Chemistry's Interdisciplinary Prize and was named on the Medicine Maker Power List 2025.
• The addressable proteome is expanding.
• There is a mismatch between drug discovery timelines and venture capital funding cycles.
• Recent advancements have challenged the belief that peptides cannot be oral drugs.
• Diversification across modalities and funding sources is essential for the pharmaceutical industry.

Clinical Implications

Understanding the funding landscape can help stakeholders navigate the complexities of drug development timelines.

Conclusion

Evolving scientific paradigms and funding strategies are important in advancing drug discovery.

Related Resources & Content

1. the medicine maker, The Medicine Maker, 2026 -- Musings from The Power List: Ali Pashazadeh
2. the analytical scientist, The Analytical Scientist, 2015 -- The Emotive List?
3. the analytical scientist, The Analytical Scientist, 2023 -- A Future-Focused Power List
4. the analytical scientist, The Analytical Scientist, 2021 -- Musings from the Power List: Gary Hieftje
5. European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids - Baudin - 2026 - Journal of Neuroendocrinology - Wiley Online Library
6. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice
7. Bicycle Therapeutics - Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) + pembrolizumab in patients with previously untreated locally advanced/metastatic urothelial carcinoma - Bicycle Therapeutics
8. Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - Merck.com
9. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections–Selection of Antibiotic Therapy for Complicated Urinary Tract Infections | Clinical Infectious Diseases | Oxford Academic
11. IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections